Haiyan Hu

7PUBLICATIONS
58CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsHaematological tumoursMolecular medicine
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Mar 28, 2026
Pan-Cancer Analysis Identifies SNORA12 as a Prognostic Biomarker and Demonstrates Its Role in Upregulating TIGIT in Osteosarcoma.

Weiwei He, Wenbo Shi, Qian Li

|Nov 25, 2025
Apatinib plus ifosfamide and etoposide versus ifosfamide and etoposide in patients with advanced osteosarcomas (OAIE/PKUPH-sarcoma 11): a randomized phase II study.

Lu Xie, Jie Xu, Xin Sun

|Feb 07, 2023
Macrophages promote anti-androgen resistance in prostate cancer bone disease.

Xue-Feng Li, Cigdem Selli, Han-Lin Zhou

|Dec 05, 2022
First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: An Open-Label Phase I/II Trial of the Anti-PD-L1 Antibody ZKAB001.

Yan Zhou, Qingcheng Yang, Yang Dong

|Oct 28, 2022
Characterization of the tumour microenvironment phenotypes in malignant tissues and pleural effusion from advanced osteoblastic osteosarcoma patients.

Zhichang Zhang, Weiping Ji, Jin Huang

|Jul 08, 2022
Stabilization of SAMHD1 by NONO is crucial for Ara-C resistance in AML.

Feifei Zhang, Jun Sun, Xiaofeng Tang

Pageof 2

Frequent Collaborators

2 joint publications

Yingqi Hua

2 joint publications

Jianjun Zhang

1 joint publications

Xue-Feng Li

1 joint publications

Cigdem Selli